ACE-D: Accelerating Cognition-guided Signatures to Enhance translation in Depression
Overview
This project is part of the National Institute for Health’s Individually Measured Phenotypes to Advance Computational Translation in Mental Health initiative, to develop a diagnosis and treatment tool for depressive disorders. Dr. Leanne Williams and her team aim to revolutionize depression treatment by creating personalized tools based on individual brain patterns. With a grant and a pool of 4,500 participants, we will use brain imaging, computer tests, and a smartphone app to identify unique cognitive biotypes for depression. Our goal is to develop a tool that can pinpoint specific types of depression and guide tailored treatment plans, potentially doubling the current success rate. This approach addresses the urgent need for better depression management, given its widespread impact and economic burden. Please see Stanford press release for more information.
Goals
A major obstacle to advancing precision psychiatry is the lack of individual-level measures suited to clinical decisions. We will optimize and validate a clinical signature measuring a cognitive phenotype linked to treatment non-response and disability in depression, enabling individualized prediction of risk and treatment selection.
Meet the Team
Leanne Williams, PhD
Principal Investigator, Stanford
Olusola Ajilore, MD, PhD
Principal Investigator, UIC
Trevor Hastie, PhD
Co-investigator, Stanford
Alex Leow, MD, PhD
Co-investigator, UIC
Alan Schatzberg, MD
Co-investigator, Stanford
Jun Ma, MD, PhD
Principal Investigator, UIC
Laura Hack, MD, PhD
Co-Investigator, Stanford
Booil Jo, PhD
Co-investigator, Stanford
Ruth O'Hara, PhD
Co-Investigator, Stanford
Peter Van Roessel, MD, PhD
Co-Investigator, Stanford
Funding
ACE-D is funded through an NIH initiative, Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH).
​
Grant: U01MH136062